Broken String Biosciences is a genomics company that develops technology platforms to accelerate the characterization of novel genome editing technologies. Its core technology, INDUCE-seq, is a DNA break-mapping platform that enables drug developers to evaluate the specificity of gene-editing tools and assess off-target genetic outcomes to realize the therapeutic benefit of gene editing.
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
| Ownership Private Company |
| Funding Series A |
Broken String Biosciences develops DNA break-mapping technology, specifically the INDUCE-seq platform, to assess the specificity and off-target genetic outcomes of genome-editing tools.
The company provides a technology platform (INDUCE-seq) to drug developers for the characterization of genome-editing technologies and off-target genetic outcomes.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Broken String Biosciences